Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Gastroenterology | Family Medicine
Disease Category: Colorectal Cancer
Location: United States, ND

Clinical Trial Details

Overview

Research Study Summary

Metastatic Colorectal Cancer with wild-type KRAS tumors.

Purpose

Objective response rate, duration of reponse, time to response, time to progression, disease control, overall survival, to evaluate changes in patient-reported outcomes.

Patient Inclusion Criteria:

  • 18 + years
  • Diagnosis of metastatic adenocarcinoma of the colon or rectum that cannot, in the opinon of the investigator, be cured by surgical resection at the time of randomization, wild-type KRAS expressing mCRC tumor, at least one uni-dimensionally measurable lesion

Patient Exclusion Criteria:

  • adiotherapy <14 days before randomization, evidence of central nervous system metastases, history of other invasive primary cancer

To Learn more
Phase

2

Gender

Both Male and Female

Age

18 and up

Overall Status

Recruiting

Facility Type

N/A

Contact

Dr. Tom Davis, Director of Business Development
Legacy Pharma Research
601 N. 5th St.
Bismarck, ND 58501
Phone: 701-751-1128
Fax: 701-751-1131

View Map

If you would like to learn more about participating in this research study, please email the trial contact using the form below.

Name:
Address:
City:
State:
Zip/Postal Code:
Country:
Phone:
Email:  
Message:
 
Please leave this field empty.

CW ID: 163099

Date Last Changed: July 24, 2013


DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.